Progress to increase shareholder value Significant positive progress has been made over past 12 months Phylogicas proprietary libraries now validated as world class Lower risk business model which generates early revenue Numerous partnering discussions underway for Phylogica to discovery Phylomer hits against 3rd party targets several Big Pharma are already engaged with new offering Deal with Roche recently closed around intracellular targets Focused internal resources on core activities Maximise financial runway (have cut burn-rate by one third) Exploring strategic international M&A opportunities for growth Remain focused on trade sale as end game typical path for other disruptive biologics discovery technologies ................................................. PYC Board now look to be more focused than they were with a previous CEO. Thats why I'm holding(long). Anyone selling at these levels will be sorry later.
PYC Price at posting:
8.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)